Bruton J, Hanke T
Vaccines (Basel). 2025; 13(1).
PMID: 39852851
PMC: 11769474.
DOI: 10.3390/vaccines13010072.
Gillespie G, Quastel M, McMichael A
Immunol Rev. 2025; 329(1):e13434.
PMID: 39753525
PMC: 11698700.
DOI: 10.1111/imr.13434.
Bilev E, Wild N, Momayyezi P, Sala B, Sun R, Sandalova T
PLoS Pathog. 2024; 20(12):e1012755.
PMID: 39652590
PMC: 11658698.
DOI: 10.1371/journal.ppat.1012755.
Murugesan G, Paterson R, Kulkarni R, Ilkow V, Suckling R, Connolly M
Nat Commun. 2024; 15(1):10126.
PMID: 39578466
PMC: 11584656.
DOI: 10.1038/s41467-024-54378-9.
Verhaar E, Gan J, Buhl S, Li Z, Horowitz A, Ploegh H
Mol Immunol. 2024; 172:56-67.
PMID: 38901180
PMC: 11257791.
DOI: 10.1016/j.molimm.2024.06.004.
SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression.
Hasan M, Claus M, Kruger N, Reusing S, Gall E, Bade-Doding C
Emerg Microbes Infect. 2024; 13(1):2361019.
PMID: 38804979
PMC: 11212573.
DOI: 10.1080/22221751.2024.2361019.
Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting.
Wallace Z, Heunis T, Paterson R, Suckling R, Grant T, Dembek M
Mol Ther. 2024; 32(3):678-688.
PMID: 38219014
PMC: 10928138.
DOI: 10.1016/j.ymthe.2024.01.010.
Non-classical HLA-E restricted CMV 15-mer peptides are recognized by adaptive NK cells and induce memory responses.
Almazan N, Sala B, Sandalova T, Sun Y, Resink T, Cichocki F
Front Immunol. 2023; 14:1230718.
PMID: 37809084
PMC: 10552778.
DOI: 10.3389/fimmu.2023.1230718.
The complex HLA-E-nonapeptide in Behçet disease.
Castano-Nunez A, Montes-Cano M, Garcia-Lozano J, Ortego-Centeno N, Garcia-Hernandez F, Espinosa G
Front Immunol. 2023; 14:1080047.
PMID: 37638008
PMC: 10449640.
DOI: 10.3389/fimmu.2023.1080047.
High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation.
Huisman B, Guan N, Ruckert T, Garner L, Singh N, McMichael A
Nat Commun. 2023; 14(1):4809.
PMID: 37558657
PMC: 10412585.
DOI: 10.1038/s41467-023-40220-1.
Oyez, Oyez, Oyez!.
Saunders P, Brooks A, Rossjohn J
Nat Immunol. 2023; 24(7):1052-1053.
PMID: 37308666
DOI: 10.1038/s41590-023-01541-x.
Intracellular trafficking of HLA-E and its regulation.
He W, Gea-Mallorqui E, Colin-York H, Fritzsche M, Gillespie G, Brackenridge S
J Exp Med. 2023; 220(8).
PMID: 37140910
PMC: 10165540.
DOI: 10.1084/jem.20221941.
Role of MHC class I pathways in antigen presentation.
Witt K
Front Cell Infect Microbiol. 2023; 13:1107884.
PMID: 37009503
PMC: 10050577.
DOI: 10.3389/fcimb.2023.1107884.
MR1- and HLA-E-Dependent Antigen Presentation of .
Kim S, Karamooz E
Int J Mol Sci. 2022; 23(22).
PMID: 36430890
PMC: 9693577.
DOI: 10.3390/ijms232214412.
What a Difference an Amino Acid Makes: An All-Atom Simulation Study of Nonameric Peptides in Inhibitory HLA-E/NKG2A/CD94 Immune Complexes.
Prasnikar E, Perdih A, Borisek J
Front Pharmacol. 2022; 13:925427.
PMID: 35991867
PMC: 9385950.
DOI: 10.3389/fphar.2022.925427.
Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes.
Walters L, Rozbesky D, Harlos K, Quastel M, Sun H, Springer S
Cell Rep. 2022; 39(11):110959.
PMID: 35705051
PMC: 9380258.
DOI: 10.1016/j.celrep.2022.110959.
Antigen presentation by MHC-E: a putative target for vaccination?.
Voogd L, Ruibal P, Ottenhoff T, Joosten S
Trends Immunol. 2022; 43(5):355-365.
PMID: 35370095
PMC: 9058203.
DOI: 10.1016/j.it.2022.03.002.
Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.
Li D, Brackenridge S, Walters L, Swanson O, Harlos K, Rozbesky D
Commun Biol. 2022; 5(1):271.
PMID: 35347236
PMC: 8960791.
DOI: 10.1038/s42003-022-03183-5.
Structure-guided stabilization of pathogen-derived peptide-HLA-E complexes using non-natural amino acids conserves native TCR recognition.
Barber C, Arena De Souza V, Paterson R, Martin-Urdiroz M, Mulakkal N, Srikannathasan V
Eur J Immunol. 2022; 52(4):618-632.
PMID: 35108401
PMC: 9306587.
DOI: 10.1002/eji.202149745.
Lesion human leukocyte antigen-E is associated with favourable prognosis for patients with oesophageal squamous cell carcinoma.
Xu Y, Du X, Li Z, Fang Z, Zhang F
J Int Med Res. 2021; 49(10):3000605211047278.
PMID: 34617814
PMC: 8504691.
DOI: 10.1177/03000605211047278.